Navigation Links
Age, Other Illnesses May Make Prostate Cancer Treatment Unnecessary
Date:5/21/2013

TUESDAY, May 21 (HealthDay News) -- Aggressive treatment for prostate cancer may not be warranted for many older patients with underlying medical conditions, a new study finds.

Treatments for prostate cancer, such as surgery, radiation and radioactive seed implants, can cause serious side effects, such as erectile dysfunction, urinary incontinence and bowel problems, explained researchers from the University of California, Los Angeles (UCLA).

They found that older patients with slower growing forms of prostate cancer who have at least three other health problems are more likely to die of something other than cancer. The findings might help educate patients on the risks and benefits of treatment, the team said.

"For men with low- to intermediate-risk disease, prostate cancer is an indolent [slow-growing] disease that doesn't pose a major risk to survival," study author Timothy Daskivich said in a university news release. "The take home point from this study is that older men with multiple underlying health problems should carefully consider whether they should treat these tumors aggressively, because that treatment comes with a price," said Daskivich, who is Robert Wood Johnson fellow at UCLA.

In the study, the researchers analyzed the 14-year survival outcomes of 3,000 men diagnosed with prostate cancer between 1994 and 1995. Within six months of their diagnosis, the men completed surveys to document any other medical conditions they had.

Daskivich's team focused on older patients with three or more underlying health problems, such as diabetes, hypertension, congestive heart failure and/or arthritis.

They found the 10-year risk of dying from something other than prostate cancer for men aged 61 to 74 was 40 percent, and the 14-year risk of dying from low or intermediate risk prostate cancer was only 3 percent.

For men older than 75, the 10-year risk of dying from something other than cancer was 71 percent and their 14-year risk of dying from prostate cancer was only 7 percent.

"This was a great opportunity to get a glimpse at the long-term outcomes of these men diagnosed with prostate cancer in the mid-1990s," Daskivich said, and "the risk of dying from their cancer paled in comparison to the risk that they'd die from something else."

His advice: "If you're very unlikely to benefit from treatment, then don't run the risk and end up dealing with side effects that can significantly impact quality of life. It's important for these men to talk to their doctors about the possibility of forgoing aggressive treatment. We're not talking about restricting care, but the patient should be fully informed about their likelihood of surviving long enough to benefit from treatment."

The study authors pointed out it may take eight to 10 years for the survival benefits of treatment to emerge. In many cases, they said, closely monitoring prostate cancer is better than treating the disease as aggressively as possible.

The researchers noted however that men with high-risk forms of prostate cancer may still benefit from aggressive treatment. The study found that older men's 14-year risk of death from high-risk prostate cancer was 18 percent.

According to the U.S. National Cancer Institute, in 2013 nearly 240,000 American men are expected to develop prostate cancer.

The study was published online on May 21 in Annals of Internal Medicine.

More information

The U.S. National Cancer Institute provides more information on prostate cancer.

-- Mary Elizabeth Dallas

SOURCE: University of California, Los Angeles, news release, May 20, 2013.


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New insights into when beach sand may become unsafe for digging and other contact
2. Chemotherapy proves life-saving for some leukemia patients who fail induction therapy
3. Immunotherapy for elderly cancer patients finds new promise in drug combination
4. Adding drug to standard chemotherapy provides no survival benefit for older lung cancer patients
5. Concerns about MRSA for expectant mothers may be unfounded
6. Another Drug Take-Back Day Scheduled for Saturday
7. Low-Income Mothers May Overfeed Their Infants
8. New global report says US lags behind 130 other nations in preterm birth rate
9. Screening for Other Health Problems May Aid COPD Survival
10. Stem cell sparing radiotherapy for head and neck cancer may avoid salivary gland damage
11. Genetic predictor of breast cancer response to chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Age, Other Illnesses May Make Prostate Cancer Treatment Unnecessary
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Final Cut Pro X users can now reveal the media of their split ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many of ... beholder, according to experts who offered insights and commentary in the current issue of ... full issue, click here . , For the American Society of Clinical Oncology ...
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
Breaking Medicine Technology: